{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:13:19Z","timestamp":1655485999392},"reference-count":46,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:p>Loss of Pten in the KrasG12D;Amhr2-Cre mutant mice leads to the transformation of ovarian surface epithelial (OSE) cells and rapid development of low-grade, invasive serous adenocarcinomas. Tumors occur with 100% penetrance and express elevated levels of wild-type tumor repressor protein 53 (TRP53). To test the functions of TRP53 in the Pten;Kras (Trp53+) mice, we disrupted the Trp53 gene yielding Pten;Kras(Trp53\u2212) mice. By comparing morphology and gene expression profiles in the Trp53+ and Trp53\u2212 OSE cells from these mice, we document that wild-type TRP53 acts as a major promoter of OSE cell survival and differentiation: cells lacking Trp53 are transformed yet are less adherent, migratory, and invasive and exhibit a gene expression profile more like normal OSE cells. These results provide a new paradigm: wild-type TRP53 does not preferentially induce apoptotic or senescent related genes in the Pten;Kras(Trp53+) cancer cells but rather increases genes regulating DNA repair, cell cycle progression, and proliferation and decreases putative tumor suppressor genes. However, if TRP53 activity is forced higher by exposure to nutlin-3a (a mouse double minute-2 antagonist), TRP53 suppresses DNA repair genes and induces the expression of genes that control cell cycle arrest and apoptosis. Thus, in the Pten;Kras(Trp53+) mutant mouse OSE cells and likely in human TP53+ low-grade ovarian cancer cells, wild-type TRP53 controls global molecular changes that are dependent on its activation status. These results suggest that activation of TP53 may provide a promising new therapy for managing low-grade ovarian cancer and other cancers in humans in which wild-type TP53 is expressed.<\/jats:p>","DOI":"10.1210\/en.2011-2131","type":"journal-article","created":{"date-parts":[[2012,3,7]],"date-time":"2012-03-07T05:24:07Z","timestamp":1331097847000},"page":"1638-1648","source":"Crossref","is-referenced-by-count":20,"title":["Wild-Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell Survival"],"prefix":"10.1210","volume":"153","author":[{"given":"Lisa K.","family":"Mullany","sequence":"first","affiliation":[{"name":"Departments of Molecular and Cellular Biology (L.K.M., Z.L., J.S.R.), Houston Texas 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilin","family":"Liu","sequence":"first","affiliation":[{"name":"Departments of Molecular and Cellular Biology (L.K.M., Z.L., J.S.R.), Houston Texas 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin R.","family":"King","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, and Gynecologic Oncology and Reproductive Medicine (E.R.K., K.-K.W.), The University of Texas M. D. Anderson Cancer Center, Houston Texas 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong-Kwok","family":"Wong","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, and Gynecologic Oncology and Reproductive Medicine (E.R.K., K.-K.W.), The University of Texas M. D. Anderson Cancer Center, Houston Texas 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnne S.","family":"Richards","sequence":"first","affiliation":[{"name":"Departments of Molecular and Cellular Biology (L.K.M., Z.L., J.S.R.), Houston Texas 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2012,3,6]]},"reference":[{"key":"2020071612213664800_B1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation.","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2020071612213664800_B2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer.","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"2020071612213664800_B3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/path.2783","article-title":"Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo.","volume":"223","author":"Jackson","year":"2011","journal-title":"J Pathol"},{"key":"2020071612213664800_B4","doi-asserted-by":"crossref","first-page":"932371","DOI":"10.1155\/2010\/932371","article-title":"Ovarian cancer pathogenesis: a model in evolution.","volume":"2010","author":"Karst","year":"2010","journal-title":"J Oncol"},{"key":"2020071612213664800_B5","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"2020071612213664800_B6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/IGC.0b013e3181d6de3f","article-title":"An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.","volume":"20","author":"Mishra","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"2020071612213664800_B7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms.","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"2020071612213664800_B8","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1038\/onc.2011.70","article-title":"Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.","volume":"30","author":"Mullany","year":"2011","journal-title":"Oncogene"},{"key":"2020071612213664800_B9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","article-title":"A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.","volume":"109","author":"Folkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2020071612213664800_B10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1525-1438.2007.01039.x","article-title":"Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.","volume":"18","author":"Salani","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"2020071612213664800_B11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"key":"2020071612213664800_B12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"2020071612213664800_B13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4161\/cc.6.2.3789","article-title":"p53 induced growth arrest versus apoptosis and its modulation by survival cytokines.","volume":"6","author":"Liebermann","year":"2007","journal-title":"Cell Cycle"},{"key":"2020071612213664800_B14","first-page":"21","article-title":"Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels.","volume":"7","author":"Ronen","year":"1996","journal-title":"Cell Growth Differ"},{"key":"2020071612213664800_B15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jmb.2005.03.014","article-title":"Comparative binding of p53 to its promoter and DNA recognition elements.","volume":"348","author":"Weinberg","year":"2005","journal-title":"J Mol Biol"},{"key":"2020071612213664800_B16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00109-011-0735-5","article-title":"Metabolic regulation by p53.","volume":"89","author":"Maddocks","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"2020071612213664800_B17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1083\/jcb.201009059","article-title":"p53 and its mutants in tumor cell migration and invasion.","volume":"192","author":"Muller","year":"2011","journal-title":"J Cell Biol"},{"key":"2020071612213664800_B18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease.","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2020071612213664800_B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome.","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"2020071612213664800_B20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors.","volume":"127","author":"Martins","year":"2006","journal-title":"Cell"},{"key":"2020071612213664800_B21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo.","volume":"445","author":"Ventura","year":"2007","journal-title":"Nature"},{"key":"2020071612213664800_B22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"2020071612213664800_B23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1172\/JCI44504","article-title":"Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.","volume":"121","author":"Wang","year":"2011","journal-title":"J Clin Invest"},{"key":"2020071612213664800_B24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma.","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2020071612213664800_B25","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1158\/0008-5472.CAN-08-3363","article-title":"Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.","volume":"69","author":"Fan","year":"2009","journal-title":"Cancer Res"},{"key":"2020071612213664800_B26","doi-asserted-by":"crossref","first-page":"27362","DOI":"10.1074\/jbc.M300547200","article-title":"Tumor suppressor p53 and its homologue p73\u03b1 affect cell migration.","volume":"278","author":"Sablina","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071612213664800_B27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1242\/dev.020560","article-title":"Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicular development and ovulation.","volume":"135","author":"Fan","year":"2008","journal-title":"Development"},{"key":"2020071612213664800_B28","first-page":"3668","article-title":"Comparative properties of five human ovarian adenocarcinoma cell lines.","volume":"45","author":"Buick","year":"1985","journal-title":"Cancer Res"},{"key":"2020071612213664800_B29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","article-title":"The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.","volume":"123","author":"King","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2020071612213664800_B30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data.","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"2020071612213664800_B31","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics.","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"2020071612213664800_B32","doi-asserted-by":"crossref","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","article-title":"Cluster analysis and display of genome-wide expression patterns.","volume":"95","author":"Eisen","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612213664800_B33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2144\/03342mt01","article-title":"TM4: a free, open-source system for microarray data management and analysis.","volume":"34","author":"Saeed","year":"2003","journal-title":"Biotechniques"},{"key":"2020071612213664800_B34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/onc.2010.413","article-title":"p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation.","volume":"30","author":"Xia","year":"2011","journal-title":"Oncogene"},{"key":"2020071612213664800_B35","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071612213664800_B36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/carcin\/bgq101","article-title":"p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.","volume":"31","author":"Molchadsky","year":"2010","journal-title":"Carcinogenesis"},{"key":"2020071612213664800_B37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1947601911410224","article-title":"p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome.","volume":"2","author":"Spike","year":"2011","journal-title":"Genes Cancer"},{"key":"2020071612213664800_B38","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1158\/0008-5472.CAN-07-1515","article-title":"Identification of an integrated SV40 T\/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.","volume":"67","author":"Deeb","year":"2007","journal-title":"Cancer Res"},{"key":"2020071612213664800_B39","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1101\/gad.10.19.2438","article-title":"p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells.","volume":"10","author":"Chen","year":"1996","journal-title":"Genes Dev"},{"key":"2020071612213664800_B40","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1038\/sj.onc.1205974","article-title":"Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.","volume":"21","author":"Qian","year":"2002","journal-title":"Oncogene"},{"key":"2020071612213664800_B41","first-page":"1389","article-title":"Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.","volume":"63","author":"Connolly","year":"2003","journal-title":"Cancer Res"},{"key":"2020071612213664800_B42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2011.03.027","article-title":"Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU\/epirubicin\/cyclophosphamide in human breast cancer.","volume":"307","author":"Oshima","year":"2011","journal-title":"Cancer Lett"},{"key":"2020071612213664800_B43","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1242\/jcs.013029","article-title":"Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.","volume":"121","author":"Astanehe","year":"2008","journal-title":"J Cell Sci"},{"key":"2020071612213664800_B44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s000180050269","article-title":"The role of p53 in tumour suppression: lessons from mouse models.","volume":"55","author":"Attardi","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"2020071612213664800_B45","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1101\/gad.1484707","article-title":"Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1\/2 and MRCK\u03b1 kinases.","volume":"21","author":"Lefort","year":"2007","journal-title":"Genes Dev"},{"key":"2020071612213664800_B46","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1128\/MCB.01816-08","article-title":"p53 suppresses Src-induced podosome and rosette formation and cellular invasiveness through the upregulation of caldesmon.","volume":"29","author":"Mukhopadhyay","year":"2009","journal-title":"Mol Cell Biol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/4\/1638\/8978148\/endo1638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/153\/4\/1638\/8978148\/endo1638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:59:31Z","timestamp":1641063571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/153\/4\/1638\/2423774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2011-2131","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,6]]}}}